Format

Send to

Choose Destination
Clin Pharmacol Ther. 2010 Dec;88(6):757-9. doi: 10.1038/clpt.2010.242.

Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations.

Author information

1
Department of Paediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. bcarleton@popi.ubc.ca

Abstract

Interpretable and meaningful pharmacogenetic data are dependent on accurate characterization of phenotypes. High-quality reports are critical, and important clinical data must not be omitted. Adequate funding to fully support dedicated program personnel is essential to meet this requirement because an "employee-driven" network that funds its surveillance clinicians is likely to be more effective than a voluntary surveillance model in capturing both adequate numbers of cases and well-characterized clinical data for rigorous phenotyping.

PMID:
21081946
DOI:
10.1038/clpt.2010.242
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center